Epidermal Growth Factor Receptor Gene Amplification in Patients
with Advanced-stage NSCLC

J 2016

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Marek MINARIK; Lucie BENESOVA et al.

Základní údaje

Originální název

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC

Autoři

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Marek MINARIK; Lucie BENESOVA; Ondrej SOREJS; Martin SVATON; Zbyněk BORTLÍČEK; Radek KUCERA a Ondrej TOPOLCAN

Vydání

Anticancer Research, Athens, The International Institute of Anticancer Research, 2016, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.937

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00089328

Organizační jednotka

Lékařská fakulta

UT WoS

000367450000065

Klíčová slova anglicky

Non-small cell lung cancer; epidermal growth factor gene; gene amplification; tyrosine kinase inhibitors

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 8. 2016 14:27, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. Patients and Methods: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. Results: EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. Conclusion: EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.

Citovat

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Marek MINARIK; Lucie BENESOVA; Ondrej SOREJS; Martin SVATON; Zbyněk BORTLÍČEK; Radek KUCERA a Ondrej TOPOLCAN. Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. Anticancer Research. Athens: The International Institute of Anticancer Research, 2016, roč. 36, č. 1, s. 455-460. ISSN 0250-7005.

@article{1333793,
   author = {Fiala, Ondrej and Pesek, Milos and Finek, Jindrich and Minarik, Marek and Benesova, Lucie and Sorejs, Ondrej and Svaton, Martin and Bortlíček, Zbyněk and Kucera, Radek and Topolcan, Ondrej},
   article_location = {Athens},
   article_number = {1},
   keywords = {Non-small cell lung cancer; epidermal growth factor gene; gene amplification; tyrosine kinase inhibitors},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC},
   volume = {36},
   year = {2016}
}

TY  - JOUR
ID  - 1333793
AU  - Fiala, Ondrej - Pesek, Milos - Finek, Jindrich - Minarik, Marek - Benesova, Lucie - Sorejs, Ondrej - Svaton, Martin - Bortlíček, Zbyněk - Kucera, Radek - Topolcan, Ondrej
PY  - 2016
TI  - Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC
JF  - Anticancer Research
VL  - 36
IS  - 1
SP  - 455-460
EP  - 455-460
PB  - The International Institute of Anticancer Research
SN  - 02507005
KW  - Non-small cell lung cancer
KW  - epidermal growth factor gene
KW  - gene amplification
KW  - tyrosine kinase inhibitors
N2  - Background: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. Patients and Methods: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. Results: EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. Conclusion: EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.
ER  -

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Marek MINARIK; Lucie BENESOVA; Ondrej SOREJS; Martin SVATON; Zbyněk BORTLÍČEK; Radek KUCERA a Ondrej TOPOLCAN. Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2016, roč.~36, č.~1, s.~455-460. ISSN~0250-7005.

Přehled o publikaci